Diversity and Dominant Species of Ground Beetle Assemblages (Coleoptera: Carabidae) in Crop Rotation and Chemical Input Systems for the Northern Great Plains

Dominant carabid species present in crops and crop rotation sequences commonly used in the northern Great Plains were assessed as an initial step toward the management of carabids as natural control agents. Ground beetle populations were determined by pitfall trapping in 4 crop rotation treatments maintained under high, managed, and low levels of chemical fertilizer and pesticide inputs. Diversity and species richness among crops, rotations, and input levels were compared using 3 indices—the Shannon-Weaver Index, relative diversity, and the Hierarchical Richness Index (HRI). Four carabid species, Cyclotrachelus altemans (Casey), Poecilvs lucublandus Say, Harpalns pensylvanicus (DeGeer), and Bembidion quadrimaculatum L., comprising ≈80% of the total collected, were considered dominant species. When carabid abundance data were grouped by crop, C. altemans was the dominant species in corn and alfalfa and P. lucublandus was dominant in wheat. In soybean plots, C. altemans and P. lucublandus were equally abundant. The relative abundance of H. pensylvanicus was highest in the low-input plots. High values of HRI for carabid diversity and species richness in the managed plots suggested that reduced chemical inputs encouraged greater abundance and diversity of beneficial carabids than were found in the high-input plots without the loss of yield seen in the low-input plots

Diversity and Dominant Species of Ground Beetle Assemblages (Coleoptera: Carabidae) in Crop Rotation and Chemical Input Systems for the Northern Great Plains

Dominant carabid species present in crops and crop rotation sequences commonly used in the northern Great Plains were assessed as an initial step toward the management of carabids as natural control agents. Ground beetle populations were determined by pitfall trapping in 4 crop rotation treatments maintained under high, managed, and low levels of chemical fertilizer and pesticide inputs. Diversity and species richness among crops, rotations, and input levels were compared using 3 indices—the Shannon-Weaver Index, relative diversity, and the Hierarchical Richness Index (HRI). Four carabid species, Cyclotrachelus altemans (Casey), Poecilvs lucublandus Say, Harpalns pensylvanicus (DeGeer), and Bembidion quadrimaculatum L., comprising ≈80% of the total collected, were considered dominant species. When carabid abundance data were grouped by crop, C. altemans was the dominant species in corn and alfalfa and P. lucublandus was dominant in wheat. In soybean plots, C. altemans and P. lucublandus were equally abundant. The relative abundance of H. pensylvanicus was highest in the low-input plots. High values of HRI for carabid diversity and species richness in the managed plots suggested that reduced chemical inputs encouraged greater abundance and diversity of beneficial carabids than were found in the high-input plots without the loss of yield seen in the low-input plots

Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B‐cell lymphoma treated with CHOP‐based chemotherapy

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/134181/1/ajh24465_am.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/134181/2/ajh24465.pd

Elara: A Phase 2 Trial Investigating The Efficacy And Safety Of Tisagenlecleucel In Adult Patients With Refractory/Relapsed Follicular Lymphoma

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/149492/1/hon6_2632.pd

Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions

Checkpoint inhibitor (CPI) therapy with anti-PD-1 antibodies has been associated with mixed outcomes in small cohorts of patients with relapsed aggressive B-cell lymphomas after CAR-T failure. To define CPI therapy efficacy more definitively in this population, we retrospectively evaluated clinical outcomes in a large cohort of 96 patients with aggressive B-cell lymphomas receiving CPI therapy after CAR-T failure across 15 US academic centers. Most patients (53%) had diffuse large B-cell lymphoma, were treated with axicabtagene ciloleucel (53%), relapsed early (≤180 days) after CAR-T (83%), and received pembrolizumab (49%) or nivolumab (43%). CPI therapy was associated with an overall response rate of 19% and a complete response rate of 10%. Median duration of response was 221 days. Median progression-free survival (PFS) and overall survival (OS) were 54 and 159 days, respectively. Outcomes to CPI therapy were significantly improved in patients with primary mediastinal B-cell lymphoma. PFS (128 vs 51 days) and OS (387 vs 131 days) were significantly longer in patients with late (>180 days) vs early (≤180 days) relapse after CAR-T. Grade ≥3 adverse events occurred in 19% of patients treated with CPI. Most patients (83%) died, commonly because of progressive disease. Only 5% had durable responses to CPI therapy. In the largest cohort of patients with aggressive B-cell lymphoma treated with CPI therapy after CAR-T relapse, our results reveal poor outcomes, particularly among those relapsing early after CAR-T. In conclusion, CPI therapy is not an effective salvage strategy for most patients after CAR-T, where alternative approaches are needed to improve post-CAR-T outcomes

Investigation of Griffithsin's Interactions with Human Cells Confirms Its Outstanding Safety and Efficacy Profile as a Microbicide Candidate

Many natural product-derived lectins such as the red algal lectin griffithsin (GRFT) have potent in vitro activity against viruses that display dense clusters of oligomannose N-linked glycans (NLG) on their surface envelope glycoproteins. However, since oligomannose NLG are also found on some host proteins it is possible that treatment with antiviral lectins may trigger undesirable side effects. For other antiviral lectins such as concanavalin A, banana lectin and cyanovirin-N (CV-N), interactions between the lectin and as yet undescribed cellular moieties have been reported to induce undesirable side effects including secretion of inflammatory cytokines and activation of host T-cells. We show that GRFT, unlike CV-N, binds the surface of human epithelial and peripheral blood mononuclear cells (PBMC) through an exclusively oligosaccharide-dependent interaction. In contrast to several other antiviral lectins however, GRFT treatment induces only minimal changes in secretion of inflammatory cytokines and chemokines by epithelial cells or human PBMC, has no measureable effect on cell viability and does not significantly upregulate markers of T-cell activation. In addition, GRFT appears to retain antiviral activity once bound to the surface of PBMC. Finally, RNA microarray studies show that, while CV-N and ConA regulate expression of a multitude of cellular genes, GRFT treatment effects only minimal alterations in the gene expression profile of a human ectocervical cell line. These studies indicate that GRFT has an outstanding safety profile with little evidence of induced toxicity, T-cell activation or deleterious immunological consequence, unique attributes for a natural product-derived lectin